FDA tells Pharma not to fret about proving PCSK9 inhibitors reduce heart attacks

The FDA tried to ease the concerns of drugmakers Thursday when it said that companies working on a new class of cholesterol-lowering drugs known as PCSK9 inhibitors, may not have to prove they also reduce the risks or heart attacks and strokes. The industry got concerned after two medical groups this week put out new guidelines suggesting doctors drop their emphasis on specific targets for lowering "bad" LDL cholesterol levels and focus also on using drugs that cut their risks for heart attack and stroke. Story | More

Suggested Articles

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.